NDC 72934-4024

BETAMETHASONE DIPROPIONATE 0.05% / MINOXIDIL 5% / NIACINAMIDE 2% / PENTOXIFYLLINE 0.5%

Betamethasone Dipropionate 0.05% / Minoxidil 5% / Niacinamide 2% / Pentoxifylline 0.5%

BETAMETHASONE DIPROPIONATE 0.05% / MINOXIDIL 5% / NIACINAMIDE 2% / PENTOXIFYLLINE 0.5% is a Topical Solution in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida, Llc. The primary component is Pentoxifylline; Betamethasone Dipropionate; Minoxidil; Niacinamide.

Product ID72934-4024_88612417-d10c-6a2b-e053-2995a90a7266
NDC72934-4024
Product TypeHuman Prescription Drug
Proprietary NameBETAMETHASONE DIPROPIONATE 0.05% / MINOXIDIL 5% / NIACINAMIDE 2% / PENTOXIFYLLINE 0.5%
Generic NameBetamethasone Dipropionate 0.05% / Minoxidil 5% / Niacinamide 2% / Pentoxifylline 0.5%
Dosage FormSolution
Route of AdministrationTOPICAL
Marketing Start Date2019-05-09
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida, LLC
Substance NamePENTOXIFYLLINE; BETAMETHASONE DIPROPIONATE; MINOXIDIL; NIACINAMIDE
Active Ingredient Strength2 g/100g; g/100g; g/100g; g/100g
Pharm ClassesBlood Viscosity Reducer [EPC],Hematologic Activity Alteration [PE],Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA],Arteriolar Vasodilation [PE],Arteriolar Vasodilator [EPC]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-4024-8

60 g in 1 BOTTLE, GLASS (72934-4024-8)
Marketing Start Date2019-05-09
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-4024-8 [72934402408]

BETAMETHASONE DIPROPIONATE 0.05% / MINOXIDIL 5% / NIACINAMIDE 2% / PENTOXIFYLLINE 0.5% SOLUTION
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-09

Drug Details

Active Ingredients

IngredientStrength
PENTOXIFYLLINE2 g/100g

Pharmacological Class

  • Blood Viscosity Reducer [EPC]
  • Hematologic Activity Alteration [PE]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]
  • Arteriolar Vasodilation [PE]
  • Arteriolar Vasodilator [EPC]
  • Blood Viscosity Reducer [EPC]
  • Hematologic Activity Alteration [PE]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]
  • Arteriolar Vasodilation [PE]
  • Arteriolar Vasodilator [EPC]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.